Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arcarios BV

This article was originally published in Start Up

Executive Summary

The field of bone disease, particularly age-related bone diseases such as osteoarthritis and osteoporosis, is a large and growing one as the global population increases and ages. The available treatment options tend to target the alleviation of symptoms rather than modifying the disease process itself. In other words, there's a high unmet medical need to identify a novel class of drug that could slow down the progression or even reverse the process of bone and cartilage degeneration. Arcarios BV aims to meet this need by using its proprietary technology platforms to discover and develop innovative drugs that will restore cartilage and bone.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel